Literature DB >> 29337638

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.

Miki Horiguchi1, Hajime Uno1, Lee-Jen Wei1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29337638     DOI： 10.1200/JCO.2017.76.0983

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544

Review 2.  Considerations for treatment duration in responders to immune checkpoint inhibitors.

Authors:  Thomas U Marron; Aideen E Ryan; Sangeetha M Reddy; Sabina Kaczanowska; Rania H Younis; Dipti Thakkar; Jiajia Zhang; Todd Bartkowiak; Rachel Howard; Kristin G Anderson; Daniel Olson; Abdul Rafeh Naqash; Ravi B Patel; Esha Sachdev; Maria E Rodriguez-Ruiz; Michal Sheffer; Sarah Church; Christopher Fuhrman; Abigail Overacre-Delgoffe; Rosa Nguyen; Vaia Florou; Jessica E Thaxton; David H Aggen; Jennifer L Guerriero
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

Review 3.  Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.

Authors:  Mengjie Jiang; Yujie Hu; Gang Lin; Chao Chen
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

Review 4.  What is the optimal duration of immune checkpoint inhibitors in malignant tumors?

Authors:  Jiaxin Yin; Yuxiao Song; Jiazhuo Tang; Bicheng Zhang
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

5.  Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Meredith M Regan; Lillian Werner; Sumati Rao; Komal Gupte-Singh; F Stephen Hodi; John M Kirkwood; Harriet M Kluger; James Larkin; Michael A Postow; Corey Ritchings; Mario Sznol; Ahmad A Tarhini; Jedd D Wolchok; Michael B Atkins; David F McDermott
Journal:  J Clin Oncol       Date:  2019-09-09       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.